Navigating DEA Compliance for Telehealth Prescriptions
Blog post from Didit
The expiration of the COVID-19 Public Health Emergency has led to a recalibration of telehealth regulations, particularly regarding the prescription of controlled substances, which were temporarily relaxed to facilitate patient access to care. The DEA is reevaluating its stance, causing uncertainty among healthcare providers who must navigate both federal and state-specific laws, as well as identity verification requirements to prevent fraud. The agency has issued a temporary rule extending certain flexibilities, allowing continued telehealth prescriptions without initial in-person exams until November 2023 for new patients and November 2024 for established relationships, while permanent rules are under consideration. Providers must stay informed about these evolving regulations and adopt robust compliance strategies, including secure communication, record-keeping, and participation in Prescription Monitoring Programs. Advanced identity verification solutions, such as those offered by Didit, are crucial in ensuring patient identity and preventing abuse, thereby supporting regulatory compliance and safeguarding the telehealth practice against legal repercussions.
No tracked trend matches for this post yet.
Use this post, company, and trend context to find content marketing opportunities, perform competitive analysis, or address product feature gaps via the Plushcap MCP server or the Plushcap API.